NasdaqGS - Delayed Quote • USD
Lexicon Pharmaceuticals, Inc. (LXRX)
At close: April 22 at 4:00 PM EDT
After hours: April 22 at 7:59 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Lonnel Coats | CEO & Director | 1.14M | -- | 1965 |
| Mr. Jeffrey L. Wade J.D. | President & CFO | 752.05k | -- | 1965 |
| Mr. Brian T. Crum | Senior VP, General Counsel & Secretary | 596.48k | -- | 1973 |
| Dr. Alan J. Main Ph.D. | Executive Vice President of Innovation & Chemical Sciences | 576.96k | -- | 1954 |
| Dr. Craig B. Granowitz M.D., Ph.D. | Senior VP & Chief Medical Officer | 652.48k | -- | 1965 |
| Ms. Kristen L. Alexander | Vice President of Finance & Accounting | -- | -- | 1968 |
| Ms. Lisa M. DeFrancesco | Head of Investor Relations & Corporate Strategy | -- | -- | 1980 |
| Mr. Dixon Terry | Vice President of Compliance | -- | -- | -- |
| Ms. Carrie Siragusa | Vice President of Marketing | -- | -- | -- |
| Ms. Desiree Gendron | Vice President of Sales & Training | -- | -- | -- |
Lexicon Pharmaceuticals, Inc.
2445 Technology Forest Boulevard
11th Floor
The Woodlands, TX 77381
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 285
Description
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Corporate Governance
Lexicon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 8; Board: 10; Shareholder Rights: 7; Compensation: 10.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- Mar 26, 2024DEF 14A: Proxy StatementsSee Full Filing
- Mar 25, 2024S-3: Offering RegistrationsSee Full Filing
- Mar 12, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Mar 11, 2024PRE 14A: Proxy StatementsSee Full Filing
- Feb 14, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing
Upcoming Events
Apr 30, 2024 - May 06, 2024
Lexicon Pharmaceuticals, Inc. Earnings Call
Related Tickers
AXSM Axsome Therapeutics, Inc.
71.10
+4.71%
IOVA Iovance Biotherapeutics, Inc.
11.32
+0.09%
MCRB Seres Therapeutics, Inc.
0.6246
+11.56%
RIGL Rigel Pharmaceuticals, Inc.
1.1300
+4.63%
EYEN Eyenovia, Inc.
0.5165
-9.48%
CDTX Cidara Therapeutics, Inc.
0.5139
-24.54%
ANVS Annovis Bio, Inc.
11.49
+14.21%
SAVA Cassava Sciences, Inc.
20.50
+4.38%
IBRX ImmunityBio, Inc.
4.9400
-6.26%
RVPH Reviva Pharmaceuticals Holdings, Inc.
3.0900
+2.32%